|1.||Whyte, Michael P: 25 articles (06/2015 - 01/2002)|
|2.||Millán, José Luis: 24 articles (12/2015 - 11/2004)|
|3.||Mornet, Etienne: 24 articles (01/2015 - 10/2002)|
|4.||Mumm, Steven: 18 articles (06/2015 - 02/2002)|
|5.||Terpos, Evangelos: 16 articles (01/2014 - 01/2003)|
|6.||Mornet, E: 15 articles (01/2012 - 01/2000)|
|7.||Orimo, Hideo: 14 articles (03/2014 - 01/2002)|
|8.||Narisawa, Sonoko: 13 articles (12/2015 - 05/2007)|
|9.||Oda, Kimimitsu: 13 articles (08/2015 - 02/2002)|
|10.||Kaiser, H E: 13 articles (11/2002 - 05/2000)|
03/01/2007 - "In the following weeks the patient general conditions and bone pain markedly improved and alkaline phosphatase returned to normal levels. "
01/01/2011 - "The ideal therapeutic option would eliminate bone pain, normalize serum total alkaline phosphatase with prolonged remission, heal radiographic osteolytic lesions, restore normal lamellar bone, and prevent recurrence and complications. "
10/01/1982 - "Parameters which improved in greater than 50% of cases included acid and alkaline phosphatase levels, pain, performance status, and measurable lesions (lung and soft tissue). "
09/21/1974 - "Treatment produced full remission of pain in a mean time of 5.5 weeks and a mean depression of serum alkaline phosphatase activity of 33%.The interval before symptomatic relief could not be predicted from the variables studied. "
01/01/2002 - "In our study, treatment reduced bone pain, fracture rate and metabolic indices of bone turnover, in particular significantly decreased bone alkaline phosphatase and cross-links (Wilcoxon test; p <0.06), and increased bone mineral density (DEXA). "
|2.||Neoplasm Metastasis (Metastasis)
08/01/2006 - "The serum levels of PSA-ACT, total PSA, free PSA, PSA density, PSA adjusted for transition zone volume, PSA-ACT density, PSA-ACT adjusted for transition zone volume, alkaline phosphatase, PSA-ACT/PSA ratio, and Gleason score in patients with bone metastases were each significantly greater than in those without bone metastases. "
05/01/1987 - "This method has proved relatively effective for bone metastasis, as reflected by bone scintigram and changes in serum alkaline phosphatase values. "
10/01/1995 - "Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases."
01/01/1981 - "The investigation of general activity of isoenzymatic spectrum of the alkaline phosphatase is helpful in differentiation of metastases into the liver and metastases into the bones. "
08/01/2014 - "This study evaluates whether alkaline phosphatase (AP) kinetics predicts bone metastasis and death in patients with CRPC. "
|3.||Body Weight (Weight, Body)
09/01/2003 - "The prolonged administration of the extract resulted in significant reduction in the alkaline phosphatase activities of the kidney and its body weight ratio (P<0.05). "
01/01/1979 - "The parameters under study included the hematocrit value; number of leukocyte differential count in both absolute and relative proportions; activity of alkaline phosphatase in neutrophil leukocytes; and body weight increase. "
02/01/2013 - "The therapeutic effect was evidenced, among others, by a higher body weight recovery, a diminished affected to total mucosal area and lower alkaline phosphatase activity in treated vs. control (TNBS treated) animals. "
01/01/2013 - "The SO and RPO significantly raised serum alkaline phosphatase levels in the SHR while body weight and renal biochemical indices were unaltered in both strains. "
05/01/2007 - "Intestinal alkaline phosphatase (IAP) is involved in the process of fat absorption, a conclusion confirmed by an altered lipid transport and a faster body weight gain from 10 to 30 wk in both male and female mice with a homozygous null mutation of the IAP coding gene (Akp3(-/-) mice). "
07/01/2012 - "Age (β = -0.62 to -0.21, P < .05) and systemic symptoms (β = 3.84-15.94, P < .05) such as pruritus were associated with lower scores from specific areas of the SF-36; serum level of alkaline phosphatase (β =-1.12 to -0.75, P < .05), and large-duct PSC (β = -15.35 to -10.05, P < .05) were associated with lower scores on mental health questionnaires. "
08/01/2011 - "In a phase II clinical trial in patients with PBC, 6E-CDCA met the primary endpoint of a reduction in alkaline phosphatase levels but safety data indicated that the drug exacerbated pruritus, one of the main symptoms of PBC, suggesting that 6E-CDCA or FXR are mediators of pruritus in humans. "
07/01/2003 - "Baseline serum alkaline phosphatase level and Mayo risk score were again independent risk factors for pruritus (P < 0.0001). "
07/01/2003 - "Serum alkaline phosphatase level and Mayo risk score were independent risk factors for pruritus (P < 0.0001). "
01/01/1999 - "Within 2 weeks of treatment onset, plasma alkaline phosphatase levels returned to normal; pruritus completely disappeared after the second session. "
01/01/2009 - "Although bone resorption markers gradually decreased throughout the study period, bone alkaline phosphatase significantly increased during the first 4 weeks and then gradually decreased. "
12/01/2014 - "In patients with monostotic disease who have a normal serum total alkaline phosphatase, we suggest that a specific marker of bone formation and bone resorption be measured, although these may still be normal. "
12/01/2014 - "After diagnosis of Paget's disease, we recommend measurement of serum total alkaline phosphatase or, when warranted, a more specific marker of bone formation or bone resorption to assess the response to treatment or evolution of the disease in untreated patients. "
11/01/2011 - "Serum levels of bone resorption marker cross-linked amino-terminal telopeptide of type I collegen (NTx), and bone formation marker bone alkaline phosphatase (BAP) were measured in both groups by enzyme-linked immunosorbent assay. "
04/01/2009 - "Postmenopausal women treated with an isopropanolic extract of Cimicifuga racemosa underwent a decrease in the urinary concentration of N-telopeptides, a marker of bone resorption, and an increase in alkaline phosphatase, a marker of bone formation, at the third month of therapy. "
|2.||Alanine Transaminase (SGPT)
|3.||Aspartate Aminotransferases (Aspartate Transaminase)
|5.||ruberythric acid (AlP)
|7.||gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)
|8.||Hydroxyproline (4 Hydroxyproline)
|1.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|4.||Renal Dialysis (Hemodialysis)